Severe Adult Atopic Dermatitis: Clinical Challenges

Facial dermatoses and use of protective mask during Covid‐19 pandemic: A clinical and psychological evaluation in patients affected by moderate–severe atopic dermatitis under treatment with dupilumab

“…This confirms the negative role of AD on the life‐quality of affected patients and underlines the importance of including the psychological indicators in clinical practice 17 . The combined use of these scores could offer a broader overview of the impact of AD on quality of life, integrating skin examination with health as perceived by the patient, representing a valuable support in the process of choosing therapy and response to treatment 18 …”

“…17 The combined use of these scores could offer a broader overview of the impact of AD on quality of life, integrating skin examination with health as perceived by the patient, representing a valuable support in the process of choosing therapy and response to treatment. 18 Finally, after 16 weeks of dupilumab treatment, a better clinical improvement was observed in the pandemic group, with a statistically significant difference (Δ EASI post-pandemic = 21.46 vs. Δ EASI prepandemic = 17.83, p-value ANCOVA = 0.0001). Choi et al evaluated allergic asthma and rhinitis incidence in adolescents before and after the SARS-COV-2 pandemic in Korea.…”

A paradoxical head and neck erythema: an adverse event due to dupilumab in adult patients with atopic dermatitis

“…Facial and neck erythemas are a barrier to achieving desired patient outcomes. Treatment of patients with severe AD is often challenging and needs a holistic approach that takes into account not only the severity of the disease but also the impact on quality of life that this disease causes, especially when it affects visible sites such as the face 5 …”

Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis

“…In everyday practice it is easy to find clinical pictures which, although not excessively extensive, do however, involve visible areas (such as face and hands) and/or genitals and therefore have a negative impact on patient quality of life but still do not reach an adequate EASI for prescription purposes. 11 Probably, 1 day, the presence of atopic comorbidities in a patient with EASI <24 will allow him to still receive dupilumab therapy in a multidisciplinary approach. Furthermore, dupilumab is a labeled drug for the treatment of both AD and CRSwNP; the use of a single drug to obtain improvement up to the near remission of AD and CRSwNP increases not only patient's compliance with the treatment but also the benefits in terms of the health cost related to these chronic diseases.…”